Brian Park, PharmD, Author at Psychiatry Advisor

The trial included 1678 children who received a third dose of the 3 µg formulation at least 2 months after the second dose of a 2-dose series at a time when Omicron was the predominant variant.

Parkinson Disease

NDA Submitted for Continuous SC Infusion Therapy for Parkinson Disease

By

Brian Park, PharmD

June 8, 2022

ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion.

General Medicine

FDA Authorizes Direct-to-Consumer Test to Detect COVID-19, Influenza, and RSV

By

Brian Park, PharmD

May 27, 2022

The test is the first non-prescription multi-analyte COVID-19 test that allows individuals to test nasal swab samples self-collected at home.

Obsessive-Compulsive and Related Disorders

TMS Device NeuroStar Cleared for Obsessive-Compulsive Disorder

By

Brian Park, PharmD

May 24, 2022

NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex.

General Medicine

FDA Declines EUA Request for Fluvoxamine for COVID-19 Treatment

By

Brian Park, PharmD

May 23, 2022

The totality of the evidence led the FDA to determine that the criteria for issuing an EUA had not been met.

Cannabis-Use Disorder

Warning Letters Sent to Companies Marketing Delta-8 THC Products as Treatments

By

Brian Park, PharmD

May 19, 2022

The FDA has expressed serious concerns related to the potential health effects for patients who have consumed delta-8 THC products.

General Medicine

Pfizer-BioNTech COVID-19 Vaccine Booster Dose Authorized for 5 to 11 Year-Olds

By

Brian Park, PharmD

May 18, 2022

The Pfizer-BioNTech COVID-19 vaccine can be administered as a single booster dose to individuals 5 to 11 years of age at least 5 months after completion of the primary series.

Brian Park, PharmD

All articles by Brian Park, PharmD

Homeopathic Med Used for Snoring Recalled Due to Microbial Contamination

Abatacept, Infliximab Improved Survival in Adults Hospitalized With COVID-19

Trial Evaluating Zuranolone for Postpartum Depression Meets All Endpoints

Pfizer-BioNTech COVID-19 Vaccine Elicits Strong Immune Response in Kids Under 5 After Third Dose

NDA Submitted for Continuous SC Infusion Therapy for Parkinson Disease

FDA Authorizes Direct-to-Consumer Test to Detect COVID-19, Influenza, and RSV

FDA Declines EUA Request for Fluvoxamine for COVID-19 Treatment

Warning Letters Sent to Companies Marketing Delta-8 THC Products as Treatments

Pfizer-BioNTech COVID-19 Vaccine Booster Dose Authorized for 5 to 11 Year-Olds

Vaccine Effectiveness Modest for Children, Teens During Omicron